Earnings
Charles River CEO Says AI-Designed Drugs Cost The Same To Safety-Test — And Pricing Power Is Still Missing
CEO Birgit Girshick expects no pricing benefit until at least the second half of next year, and says growth is almost all volume.
CRL
Charles River Laboratories (CRL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
